Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and planned statistical analysis of the LYNX-2 Phase 3 trial to evaluate phentolamine ophthalmic solution for the proposed indication for the treatment of decreased visual acuity under dim (mesopic) light conditions.
Related news for (OCUP)
- ocuphire pharma announces acquisition of opus genetics
- ocuphire pharma announces publication of full phase 3 results of phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis in ophthalmology
- update – ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia
- ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia
- Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference